Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $2.00.

A number of equities analysts have recently issued reports on the company. ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 24th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price target (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. William Blair raised Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, August 4th.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARWR. Bank of New York Mellon Corp increased its position in shares of Arrowhead Pharmaceuticals by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after acquiring an additional 11,099 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 53,500 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 3.4% in the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after purchasing an additional 21,654 shares during the last quarter. LMR Partners LLP purchased a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $467,000. Finally, Virtu KCG Holdings LLC boosted its holdings in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after purchasing an additional 53,215 shares during the last quarter. 21.44% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Arrowhead Pharmaceuticals (ARWR) opened at $3.70 on Monday. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $4.70.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals, Inc. (ARWR) Receives Consensus Recommendation of “Hold” from Analysts” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/arrowhead-pharmaceuticals-inc-arwr-receives-consensus-recommendation-of-hold-from-analysts/1728587.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.